TREATMENT AND

MANAGEMENT
•CHEMOTHERAPY
•RADIATION THERAPY
•SURGICAL
• Routinely, C-SCLC is treated based on SCLC guidelines.

• The current generally accepted standard of care for all forms of SCLC is
concurrent chemotherapy (CT) and thoracic radiation therapy (TRT) in
LD, and CT only in ED. For complete responders (patients in whom all
evidence of disease disappears), prophylactic cranial irradiation (PCI) is
also given.
• Surgery is not often considered as a treatment option in SCLC
(including c-SCLC) due to the high probability of distant metastases at
the time of diagnosis.

• Combination of cisplatin or carboplatin plus etoposide or irinotecan

are considered comparable first-line regimens for SCLC
Drugs used:
• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs)
• Erlotinib, Gefitinib, Cetuximab

• Inhibitors of vascular endothelial growth factor (VEGF)

• Bevacizumab

• Inhibitors of folate metabolism

• Pemetrexed